Therapies targeting DNA and RNA in Huntington's disease

The Lancet Neurology

Volumn 16, Issue 10, 2017, Pages 837-847

  Wild, Edward J ^a   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE SELECTIVE ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; DNA; GENE THERAPY AGENT; HUNTINGTIN; IONIS HTTRX; PEPTIDE CONJUGATED ANTISENSE OLIGONUCLEOTIDE; RNA; SMALL INTERFERING RNA; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; VIRUS VECTOR; ZINC FINGER PROTEIN;

ANTISENSE THERAPY; CRISPR-CAS9 SYSTEM; GENE TARGETING; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; MOLECULAR THERAPY; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNAI THERAPEUTICS; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOLOGICAL THERAPY; HUNTINGTON DISEASE; PROCEDURES;

ANIMALS; BIOLOGICAL THERAPY; DNA; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; RNA;

EID: 85029162851     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30280-6     Document Type: Review

References (76)

1. Ross, CA, Tabrizi, SJ, Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10 (2011), 83–98.
2. Wild, EJ, Tabrizi, SJ, Premanifest and early Huntington's disease. Bates, G, Jones, L, Tabrizi, SJ, (eds.) Huntington's Disease, 4th edn., 2014, Oxford University Press, Oxford.
3. Lee, JM, Ramos, EM, Lee, JH, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78 (2012), 690–695.
4. Ross, CA, Aylward, EH, Wild, EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10 (2014), 204–216.
5. Saudou, F, Humbert, S, The biology of Huntingtin. Neuron 89 (2016), 910–926.
6. Finkel, RS, Chiriboga, CA, Vajsar, J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388 (2016), 3017–3026.
7. US Food and Drug Administration. FDA approves first drug for spinal muscular atrophy. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534611.htm, 2016 (accessed May 21, 2017).
8. US Food and Drug Administration. Guidance for industry: guidance for human somatic cell therapy and gene therapy. Hum Gene Ther 9 (1998), 1513–1524.
9. Tartari, M, Gissi, C, Lo Sardo, V, et al. Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol Biol Evol 25 (2008), 330–338.
10. Nasir, J, Floresco, SB, O'Kusky, JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81 (1995), 811–823.
11. Bates, GP, Dorsey, R, Gusella, JF, et al. Huntington disease. Nat Rev Dis Primers, 1, 2015, 15005.
12. Mestre, T, Ferreira, J, Coelho, MM, Rosa, M, Sampaio, C, Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev, 2009 CD006455.
13. Gauthier, LR, Charrin, BC, Borrell-Pages, M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118 (2004), 127–138.
14. Dragatsis, I, Levine, MS, Zeitlin, S, Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26 (2000), 300–306.
15. Harper, SQ, Staber, PD, He, X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102 (2005), 5820–5825.
16. Franich, NR, Fitzsimons, HL, Fong, DM, Klugmann, M, During, MJ, Young, D, AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 16 (2008), 947–956.
17. McBride, JL, Pitzer, MR, Boudreau, RL, et al. Preclinical safety of RNAi-mediated HTT suppression in the Rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 19 (2011), 2152–2162.
18. Stiles, DK, Zhang, Z, Ge, P, et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 233 (2012), 463–471.
19. Grondin, R, Kaytor, MD, Ai, Y, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135 (2012), 1197–1209.
20. Mangiarini, L, Sathasivam, K, Seller, M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996), 493–506.
21. Sathasivam, K, Neueder, A, Gipson, TA, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci USA 110 (2013), 2366–2370.
22. Banez-Coronel, M, Ayhan, F, Tarabochia, AD, et al. RAN translation in Huntington disease. Neuron 88 (2015), 667–677.
23. Rue, L, Banez-Coronel, M, Creus-Muncunill, J, et al. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J Clin Invest 126 (2016), 4319–4330.
24. Vijayvargia, R, Epand, R, Leitner, A, et al. Huntingtin's spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function. eLife, 5, 2016, e11184.
25. Bennett, CF, Swayze, EE, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50 (2010), 259–293.
26. Kordasiewicz, HB, Stanek, LM, Wancewicz, EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of Huntingtin synthesis. Neuron 74 (2012), 1031–1044.
27. Leavitt, B, Tabrizi, S, Kordasiewicz, H, et al. Discovery and early clinical development of ISIS-HTTRx, the first HTT-lowering drug to be tested in patients with Huntington's disease. Neurology, 86(suppl 16), 2016 PL1.002 (abstr).
28. Hersch, S, Claassen, D, Edmondson, M, Wild, E, Guerciolini, R, Panzara, M, Multicenter, randomized, double-blind, placebo-controlled phase 1b/2a studies of WVE-120101 and WVE-120102 in patients with Huntington's disease. Neurology, 88(suppl 16), 2017 P2.006 (abstr).
29. Butler, D, Iwamoto, N, Meena, M, Svrzikapa, N, Verdine, GL, Zlatev, I, Chiral control. https://www.google.com/patents/US20150211006, 2015 (accessed May 21, 2017).
30. Datson, NA, Gonzalez-Barriga, A, Kourkouta, E, et al. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One, 12, 2017, e0171127.
31. Stanek L. Widespread gene delivery to the nonhuman primate brain for the treatment of Huntington's disease. CHDI Foundation Annual Therapeutics Conference; Palm Springs, CA, USA; Feb 23–26, 2015.
32. Miniarikova, J, Zanella, I, Huseinovic, A, et al. Design, characterization, and lead selection of therapeutic miRNAs targeting Huntingtin for development of gene therapy for Huntington's disease. Mol Ther Nucleic Acids, 5, 2016, e297.
33. Samaranch, L, Blits, B, San Sebastian, W, et al. MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. Gene Ther 24 (2017), 253–261.
34. Doherty EM. Screening approaches to identify small-molecule modulators of huntingtin protein levels. CHDI Foundation Annual Therapeutics Conference; Malta; May 11, 2017.
35. Larrouy, B, Blonski, C, Boiziau, C, et al. RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: use of backbone modification to improve specificity. Gene 121 (1992), 189–194.
36. Hutvagner, G, Simard, MJ, Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol 9 (2008), 22–32.
37. Keiser, MS, Kordasiewicz, HB, McBride, JL, Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Hum Mol Genet 25:suppl R1 (2016), R53–R64.
38. Pouladi, MA, Morton, AJ, Hayden, MR, Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 14 (2013), 708–721.
39. Agrawal, S, Kandimalla, ER, Role of Toll-like receptors in antisense and siRNA. Nat Biotechnol 22 (2004), 1533–1537.
40. Crooke, ST, Baker, BF, Kwoh, TJ, et al. Integrated safety assessment of 2′-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther 24 (2016), 1771–1782.
41. Fidler, B, Alnylam scraps RNAi drug after safety problems, shares plunge. http://www.xconomy.com/boston/2016/10/05/alnylam-scraps-rnai-drug-after-safety-problems-shares-plunge/#, Oct 5, 2016 (accessed Aug 18, 2017).
42. Chi, X, Gatti, P, Papoian, T, Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today 22 (2017), 823–833.
43. Chan, JHP, Lim, S, Wong, WSF, Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33 (2006), 533–540.
44. Lu, X-H, Yang, XW, “Huntingtin holiday”: progress toward an antisense therapy for Huntington's disease. Neuron 74 (2012), 964–966.
45. Wang, N, Gray, M, Lu, X-H, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat Med 20 (2014), 536–541.
46. Shanley, M, IONIS-HTT Rx study in HD patients completes enrollment. http://www.raredr.com/news/huntingtons-disease-therapy-study, June 21, 2017 (accessed Aug 18, 2017).
47. Byrne, LM, Wild, EJ, Cerebrospinal fluid biomarkers for Huntington's disease. J Huntingtons Dis 5 (2016), 1–13.
48. Wild, EJ, Boggio, R, Langbehn, D, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest 125 (2015), 1979–1986.
49. Miller, TM, Pestronk, A, David, W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12 (2013), 435–442.
50. Butland, SL, Devon, RS, Huang, Y, et al. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics, 8, 2007, 126.
51. Evers, MM, Pepers, BA, van Deutekom, JC, et al. Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One, 6, 2011, e24308.
52. Lee, JM, Gillis, T, Mysore, JS, et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet 90 (2012), 434–444.
53. Liu, W, Kennington, LA, Rosas, HD, et al. Linking SNPs to CAG repeat length in Huntington's disease patients. Nat Meth 5 (2008), 951–953.
54. Kay, C, Collins, JA, Skotte, NH, et al. Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry. Mol Ther 23 (2015), 1759–1771.
55. Pringsheim, T, Wiltshire, K, Day, L, Dykeman, J, Steeves, T, Jette, N, The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord 27 (2012), 1083–1091.
56. Hammond, SM, Hazell, G, Shabanpoor, F, et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci USA 113 (2016), 10962–10967.
57. Rafii, MS, A Phase II trial of AAV2-NGF in mild to moderate Alzheimer's disease. J Prev Alzheimers Dis 10 (2015), 274–275.
58. Yu, D, Pendergraff, H, Liu, J, et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant Huntingtin expression. Cell 150 (2012), 895–908.
59. Alvarez-Erviti, L, Seow, Y, Yin, H, Betts, C, Lakhal, S, Wood, MJA, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotech 29 (2011), 341–345.
60. Niewoehner, J, Bohrmann, B, Collin, L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81 (2014), 49–60.
61. Tabrizi, SJ, Scahill, RI, Owen, G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12 (2013), 637–649.
62. Deverman, BE, Pravdo, PL, Simpson, BP, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotech 34 (2016), 204–209.
63. Mingozzi, F, High, KA, Immune responses to AAV in clinical trials. Curr Gene Ther 11 (2011), 321–330.
64. Naryshkin, NA, Weetall, M, Dakka, A, et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345 (2014), 688–693.
65. Vassena, R, Heindryckx, B, Peco, R, et al. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells. Hum Reprod Update 22 (2016), 411–419.
66. Zeitler, B, Froelich, S, Yu, Q, et al. Allele-specific repression of mutant Huntingtin expression by engineered zinc finger transcriptional repressors as a potential therapy for Huntington's disease. Mol Ther, 22(suppl 1), 2014, S233 (abstr).
67. Garriga-Canut, M, Agustín-Pavón, C, Herrmann, F, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109 (2012), E3136–E3145.
68. Agustín-Pavón, C, Mielcarek, M, Garriga-Canut, M, Isalan, M, Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol Neurodegener, 11, 2016, 64.
69. Shin, JW, Kim, K-H, Chao, MJ, et al. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet 25 (2016), 4566–4576.
70. Yang, S, Chang, R, Yang, H, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease. J Clin Invest 127 (2017), 2719–2724.
71. Klug, A, The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem 79 (2010), 213–231.
72. Savić, N, Schwank, G, Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res 168 (2016), 15–21.
73. Cox, DBT, Platt, RJ, Zhang, F, Therapeutic genome editing: prospects and challenges. Nat Med 21 (2015), 121–131.
74. Tabrizi, SJ, Scahill, RI, Durr, A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10 (2011), 31–42.
75. Tabrizi, SJ, Reilmann, R, Roos, RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11 (2012), 42–53.
76. Byrne, LM, Rodrigues, FB, Blennow, K, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurol 16 (2017), 601–609.